大豪科技(603025.SH):興感半導體與華為合作仍處於供應商資質初審階段
格隆匯9月15日丨大豪科技(603025.SH)公佈,公司近日關注到部分媒體先後發佈了關於“公司投資的興感半導體主要產品電流傳感器芯片已實現批量生產並近入華為的供應商審核範圍”的相關報道。經公司與興感半導體核實:興感半導體目前與華為的合作仍處於供應商資質初步審核階段,未進入批量供貨階段。
興感半導體成立於2019年4月,註冊資本405.85萬元。2019年4月公司對興感半導體投資規模為3000萬元人民幣,佔註冊資本的24.22%,目前該公司產品僅實現小批量供貨,未達到盈虧平衡,對本公司2020年的業績影響極小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.